Cancer diagnostics company Helomics Corp. has been acquired by a group of investors, who plan to use the company’s technology to offer clinical research services while boosting the region’s business startup economy.
Franklin Park native Gerald Vardzel was among a group of investors to acquire the Lawrenceville-based company from HealthCare Royalty Partners, a health care investment firm based in Stamford, Conn. The deal closed recently.
The 51-year-old Mr. Vardzel, a University of Pittsburgh graduate, is the new Helomics president and CEO. He replaces Neil Campbell, who is no longer with the company.
“It’s great to come home,” said Mr. Vardzel, who was previously vice president, corporate development at contract research organization Global Specimen Solutions Inc. in Raleigh, N.C. “What we have right here in our backyard is a great foundation.”
Terms of the deal, which closed in the past week, were not disclosed and Mr. Vardzel said it was too early to identify the other investors.
Helomics, which employs 39 people, will leverage its expertise in developing individualized cancer treatments to offer clinical research services to the pharmaceutical and medical diagnostic industries. In addition to pharma and other private companies, Helomics will collaborate with university researchers.
Helomics will offer a wide range of services on a contract basis, tailoring services to client needs, said Don Very, research and commercial development at Helomics.
“Our differentiation will be based on developing a customized solution for each client,” he said. “It’s a very new direction.”
Precision Therapeutics Inc., the company that became Helomics in 2014, was founded in 1995. In 2005, it marketed its first product, which identified women with ovarian cancer who were resistant to platinum-based chemotherapy. In expanding its business model, Helomics becomes among only a few clinical contract research organizations in Western Pennsylvania.
Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699



Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.